CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Leukemia. Basic parameters: 60 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Monitoring Circulating Tumor DNA After Chemotherapy in Elderly Patients With Acute Leukemia
Overview
This study will monitor CtDNA After Chemotherapy in Elderly Patients With AL
Detailed description
This study will use droplet digital PCR (ddPCR) method to quantify peripheral blood plasma mutant allele frequency (MAF) in elderly acute leukemia patients after chemotherapy to evaluate the clinical value of CtDNA .
Primary outcome measures
- cumulative incidence of relapse(CIR) [Time frame: through study completion, an average of 1 year]
Secondary outcome measures (1)
- overall survival (OS) [Time frame: through study completion, an average of 2 years]
Eligibility criteria
Inclusion criteria
- Written informed consent
- Male
- not pregnant female
- patients >=60 years old
- Diagnosis of acute leukemia
Exclusion criteria
- Pregnancy
- HIV positive
- patients >=100 years old
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
China · 1 center
- Navy General Hospital — Beijing
Identifiers
NCT: NCT04157569 · NavyGHB-006